- Open Access
Neuronal self-injury mediated by IL-1β and MMP-9 in a cerebral palsy model of severe neonatal encephalopathy induced by immune activation plus hypoxia-ischemia
Journal of Neuroinflammation volume 12, Article number: 111 (2015)
Inflammation due to remote pathogen exposure combined to hypoxia/ischemia (HI) is one of the most common causes of neonatal encephalopathy affecting at-term or near-term human newborn, which will consequently develop cerebral palsy. Within term-equivalent rat brains exposed to systemic lipopolysaccharide (LPS) plus HI, it was previously showed that neurons produce IL-1β earlier than do glial cells, and that blocking IL-1 was neuroprotective. To further define the mechanisms whereby IL-1 exerts its neurotoxic effect, we hypothesize that IL-1β plays a pivotal role in a direct and/or indirect mechanistic loop of neuronal self-injury through matrix metalloproteinase (MMP)-9.
An established preclinical rat model of LPS+HI-induced neonatal encephalopathy was used. In situ hybridization, ELISA, and immunolabeling techniques were employed. Selective blocking compounds allowed addressing the respective roles of IL-1 and MMP-9.
In LPS+HI-exposed forebrains, neuronal IL-1β was first detected in infarcted neocortical and striatal areas and later in glial cells of the adjacent white matter. Neuronal IL-1β played a key role: (i) in the early post-HI exacerbation of neuroinflammation and (ii) in generating both core and penumbral infarcted cerebral areas. Systemically administered IL-1 receptor antagonist (IL-1Ra) reached the brain and bound to the neocortical and deep gray neuronal membranes. Then, IL-1Ra down-regulated IL-1β mRNA and MMP-9 neuronal synthesis. Immediately post-HI, neuronal IL-1β up-regulated cytokine-induced neutrophil chemoattractant (CINC-1), monocyte chemoattractant protein-1 (MCP-1), and inducible nitric oxide synthase. MMP-9 would disrupt the blood–brain barrier, which, combined to CINC-1 up-regulation, would play a role in polymorphonuclear cell (PMN) infiltration into the LPS+HI-exposed brain. IL-1β blockade prevented PMN infiltration and oriented the phenotype of macrophagic/microglial cells towards anti-inflammatory and neurotrophic M2 profile. IL-1β increased the expression of activated caspase-3 and of receptor-interacting-protein (RIP)-3 within infarcted forebrain area. Such apoptotic and necroptotic pathway activations were prevented by IL-1Ra, as well as ensuing cerebral palsy-like brain damage and motor impairment.
This work uncovered a new paradigm of neuronal self-injury orchestrated by neuronal synthesis of IL-1β and MMP-9. In addition, it reinforced the translational neuroprotective potential of IL-1 blockers to alleviate human perinatal brain injuries.
Hypoxia-ischemia (HI) combined to inflammation is an important pathophysiological component of neonatal encephalopathy (NE) affecting up to 1 % of newborns. Indeed, combined pathogen-induced inflammation complicated by HI was recognized as one of the most common causes of human perinatal brain damage [1–8]. Moderate and severe forms of NE lead either to death or lifelong neurodisabilities such as cerebral palsy (CP) or other neurobehavioral disabilities including learning difficulties [1, 4]. Combination of inflammation/infection plus HI has been reproduced experimentally in rodents at neurodevelopmental stages equivalent to early and late preterm development of human neonates—i.e., in rat pups between P1 and P7 [5, 9–13]. Inflammation/infection and HI have also recently been modeled in rats at a neurodevelopmental stage (P12) corresponding to full-term human neonate development. Profound differences in the neuropathological impacts from lipopolysaccharide (LPS) plus HI-induced patterns of innate immune responses have been shown between P1 and P12 rats [13, 14]. Importantly, these neuropathological differences reproduce those observed between preterm and term human newborns . Thus, LPS+HI-induced brain injury of P12 rat pups is a relevant model for the study of term human NE .
We previously showed that, within term-matched rat brains exposed to systemic LPS+HI, neurons produce IL-1β earlier than do glial cells, and that IL-1 receptor antagonist (IL-1Ra) was neuroprotective . To further define the neurotoxic mechanisms of IL-1 in the immature brain, we hypothesize that IL-1 induces directly and/or indirectly neuronal self-injury involving matrix metalloproteinase (MMP)-9, blood–brain barrier (BBB) disruption, and polymorphonuclear cell (PMN) infiltration.
Materials and methods
Our pre-clinical model was designed as previously described . Briefly, Lewis dams were obtained from Charles River Laboratories (Saint-Constant, QC, Canada) between gestational day 14 (G14) and 16 (G16). P12 pups received a single intraperitoneal (ip) injection of LPS (200 μg/kg diluted in 50 μL of saline) from Escherichia coli or saline. Ischemia was induced 4 h after LPS administration by permanent ligature of the right common carotid artery followed by 8 % oxygen exposure at 37+/− 1 °C for 1.5 h. A control (Ctl) group underwent no surgery, and a sham surgery group was submitted to the common carotid artery exposure without ligature. Because we found no observable difference in the results of these two groups, both were combined and identified as the Ctl group. Pups from each litter were randomized in three different experimental groups (Ctl, LPS+HI, LPS+HI+IL-1Ra) independently of sex and weight. The end of hypoxia is referred to as 0 h. Pups were sacrificed at 4 h (P12), 24 h (P13), 48 h (P14), and 8 days (P20) post-HI. Each session of surgery was performed in groups of 10–20 animals from 2–4 litters; our data of mortality was the mean ± SEM of mortality from each of these groups (total of 78 pups in LPS+HI condition; 72 pups in LPS+HI+IL-1Ra condition; 38 pups in Ctl condition). Some rats were kept alive until P120 for motor behavior. Rats were euthanized by rapid decapitation. The ethical review board of the Sherbrooke University approved this experimental design (protocol #147-11R). The care of animals followed internationally recognized guidelines.
Blocking experiments using IL-1Ra and MMP-9 inhibitor (SB3CT)
IL-1 receptor antagonist (IL-1Ra) was used at a concentration of 200 mg/kg. This dose has been demonstrated as the most effective in terms of neuroprotection in adult stroke models as well as in the above-mentioned model [15, 16]. The first injection was given ip, 30 min before LPS injection. Five other injections were given every 12 h thereafter. SB3CT (Sigma, ON, Canada) was used at a concentration of 12.5 mg/kg. This dose was proven effective in a mouse model of middle cerebral artery occlusion. The first injection was given before surgery, a second 4 h after HI, and another every 12 h thereafter for a total of six injections.
Brains were fixed in paraformaldehyde (PFA) 4 % at room temperature, paraffin-embedded, and cut in 5-μm slices using a microtome for histological studies. Hematoxylin-eosin (H&E) staining was used to visualize and quantify brain injuries. ImageJ analysis software (National Institutes of Health (NIH) Image, http://rsbweb.nih.gov/nih-image/) was used to measure the surface of the right hemisphere on coronal sections located at the epicenter of the infarct (Bregma −1.00). The right hemisphere surfaces of LPS- and/or HI-exposed rats were then compared with those of Ctl. So-called core vs penumbra areas of brain infarcts were defined as previously described . Briefly, core injuries were associated with infarcted areas bearing cavitary lesions, whereas penumbra lesions were identified as regions surrounding the core where pycnotic neurons or loss of normal neuronal architecture were observed.
Immunohistochemistry (IHC) and immunofluorescence (IF)
IHC and IF were performed as previously described [5, 15]. Briefly, sections were incubated overnight at 4 °C with the primary antibodies. The antibodies used are detailed in Table 1. The appropriate HRP-conjugated or Alexa Fluor-conjugated secondary Abs were used for each primary Ab and incubated for 1 h at room temperature. Labeling was revealed using diaminobenzidine (DAB) (Roche, QC, Canada). Slides were counterstained with hematoxylin. IF slides were mounted using a DAPI-containing medium (Invitrogen, ON, Canada). Negative controls consisted of an additional set of sections, treated similarly but without the primary antibody. Labeled cells were counted, and cytokine expression was analyzed using the ImageJ analysis software (NIH Image, http://rsbweb.nih.gov/nih-image/). The percentage of cells meant the number of a given cell type on the total number of cells per field (magnification ×40).
Protein extracts were prepared from right hemisphere forebrains as previously described . ELISAs were performed on these protein extracts using ELISA Kits (R&D System, MN, USA), as previously described .
In situ hybridization
mRNA encoding for IL-1β was detected and localized on brain sections using dioxigenin-UTP (DIG) labeled riboprobes. The IL-1β DNA template was amplified using primers with specific restriction enzymes: IL-1β BamHI forward 5′- AGT CCT GGA TCC ATG GCA ACT GTC CCT GAA CT -3′ and IL-1β EcoRI reverse 5′- GGC CGC GAA TTC AGC TCA TGG AGA ATA CCA CT -3′. DIG-labeled single-stranded RNA was transcribed from commercially available plasmid vectors according to manufacturer instructions (Roche, Laval, QC, Canada, 1175025). The in situ hybridization protocol used was that of Dr Jasna Kriz . Briefly, slides were dried, post-fixed in 4 % paraformaldehyde, and digested by proteinase K, after which brain sections were washed in water, in a solution of 0.1 M triethanolamine (TEA, pH 8.0), and then acetylated in 0.25 % acetic anhydride in 0.1 M TEA. Hybridization of brain sections with the riboprobe was performed overnight at 72 °C. Slides were washed in standard saline citrate (1XSSC: 0.15 M NaCl, 15 mM trisodium citrate buffer, pH 7.0) and were then incubated with anti-DIG-AP antibodies overnight at 4 °C. Next, slides were incubated with NBT/BCIP solution, for color development; at room temperature for 16 h. Slides were then washed with TBST and mounted with DAKO Cytomation Glycergel Mounting Medium. Staining intensities of IL-1β mRNA were studied by colorimetric analysis performed with ImageJ software as previously described .
Circling behavior test was performed using the open field test apparatus. Rat pups at P14 were placed in the center of the open field and videotaped for 1.5 min. The movements of the pups were scored as following: 0 = absence of circling, 1 = partial circling, 2 = total circling . The open field test was used to determine spontaneous locomotor activity and exploratory behavior from P100 to P120, as described previously . Elevated body swing test was used, as previously described, to determine long-term motor impairment from P100 to P120 . The movements of rats suspended by their tails were video-recorded. We set the threshold at an angle of 90° for an efficient upswing. Latency before the first efficient upswing, the side of the efficient upswing, and the total number of efficient upswings were recorded and compared across experimental conditions. The Turning in Alley test was performed at P100–P120, as previously described, to assess any potential persisting shift of lateralization due to motor impairment . Rats were placed facing the end of a closed alley: the duration and the side of the turning were recorded.
Data are presented as means ± SEM. Results across experimental conditions were compared using the unpaired t test with Welch correction. The statistical significance level was set at p ≤ 0.05. Data from the Ctl group and sham group were combined, as well as male and female data, because they are not significantly different.
Distribution of IL-1Ra in LPS+HI-exposed brains
hrIL-1Ra (ip injected) crossed the blood–brain barrier (BBB), bound to neurons (Fig. 1a–c), and rapidly reached a high intracerebral titer (above 2500 pg/mg) at 4 h and 24 h post HI in brains exposed to LPS+HI+IL-1Ra condition (Fig. 1a). To test whether the BBB might be permeated by an LPS+HI insult, as well as its preventability by IL-1Ra, we looked for an albumin leakage through the forebrain BBB at 4 h and 48 h post-HI ± IL-1Ra. A functional disruption of BBB in LPS+HI condition and its prevention by IL-1Ra was demonstrated by a significantly higher albumin infiltration in LPS+HI than in LPS+HI+IL-1Ra exposed brains (Fig. 1d, e). A structural disruption of BBB was also shown in LPS+HI-exposed brains at 4 h after post-LPS+HI (Fig. 1f): LPS+HI exposure disrupted the tight junction protein claudin-5 and GFAP linear/continuous expression of BBB. IL-1Ra prevented the disruptive effect of LPS+HI on the BBB (Fig. 1f).
To test whether IL-1Ra immunoreactivity detected at the surface of neurons might interfere with IL-1 function, we compared the levels of auto-activation of IL-1β synthesis between LPS+HI vs LPS+HI+IL-1Ra conditions (Fig. 2a–f). Compared to LPS+HI alone, forebrains exposed to LPS+HI+IL-1Ra presented a two to threefold drop in IL-1β mRNA (in situ hybridization) at 1 h post-HI (Fig. 2e) and in IL-1β expression (ELISA) at 24 h and 48 h post-HI (Fig. 2a). This IL-1β synthesis and its drop under IL-1Ra treatment was from neuronal cells as shown by in situ hybridization at 1 h post-HI (Fig. 2d, e) and by IHC in both core and penumbra at 4 h post-HI (Fig. 2c). IL-1Ra binding to neurons was shown by IF (NeuN+IL-1Ra+) double labeling at 4 h post-HI (Fig. 2f). The discrepancy between the diminished IL-1β detection on neuronal cell bodies by IHC at 4 h (Fig. 2c) and its absence of decrease at the same time by ELISA (Fig. 2a) might be due to the rapid binding of IL-1Ra on the neuronal IL-1Rs that would limit other IL-1 ligands binding at 4 h but without any decrease in the amount of free extracellular IL-1 at this early—but not later—time points (Fig. 2a, c).
IL-1Ra protects against LPS+HI-induced brain injury and ensuing neurobehavioral morbidity and mortality
IL-1Ra reduced LPS+HI-induced mortality (Fig. 3a). The comparison of H&E staining between brains exposed to LPS+HI vs LPS+HI+IL-1Ra showed that IL-1Ra prevented the extent of brain injury (Fig. 3b, c). IL-1Ra exerted a neuroprotective effect on both the core and penumbra components of ischemic gray and WM injuries of the forebrain (Fig. 3b, c). Behavioral experiments showed that LPS+HI-induced motor impairment was prevented by IL-1Ra at both early juvenile (P14) and late adult (P120) time points (Fig. 4). This curbing of brain injury, and subsequent motor behavior impairment, was associated with an early drop of neuronal IL-1β mRNA expression within the infarcted area, from 1 h post-LPS+HI (Fig. 2d, e). This intra-cerebral drop in IL-1β mRNA and IL-1β synthesis under IL-1Ra treatment might result from decreased activation of either neuronal nuclear factors e.g. NF-κB, or nod-like receptors (NLRs) of the inflammasome, or both. It has previously been shown that the inflammasome is activated during adult brain injury and that NLRP1 and NLRP3 (NLRs) are detected in adult neurons and macrophage/microglia, respectively . Our results showed that NLRP1 and NLRP3 remained undetectable at P1, but that NLRP1 start to be expressed in cortical and subcortical neurons at P12 (Fig. 5a); 50 % of NLRP1+ cells we observed at P12 were also NeuN+; thus, glial cells at this P12 stage of development in rats also expressed NLRP1. NLRP3 was not detected at P1 or P12, but was at P40 in macrophage/microglial cells though not in neurons (Fig. 5b). This means that NLRP1 driven inflammasome might play a role within LPS+HI-exposed neurons to trigger IL-1β release.
IL-1Ra interferes with key neuroinflammatory mediators and prevents LPS+HI-induced PMN recruitment and amoeboid M1 pro-inflammatory polarization of macrophage/microglia
IL-1Ra prevented PMN infiltration within LPS+HI-exposed brains at 48 h (Fig. 6a, b). IL-1Ra also curbed the induction of IL-1β-driven PMN-recruiting chemokine CINC-1 (cytokine-induced neutrophil chemoattractant-1) at 4 and 24 h—by respectively threefold and twofold—within the LPS+HI injured forebrain (Fig. 6c, d).
IL-1Ra had no effect on the total number of macrophage detected within LPS+HI injured brain areas (Fig. 7a). The proportion of inducible nitric oxide synthase (iNOS) positive cells significantly decreased within LPS+HI+IL-1Ra—compared to LPS+HI—affected forebrains (Fig. 7b, f). On the other hand, following IL-1Ra administration, the proportion of arginase 1 (Arg1)-positive microglia/macrophages—i.e., M2 polarized macrophages—significantly rose within LPS+HI+IL-1Ra- compared to LPS+HI-exposed forebrains (Fig. 7c, g). Under IL-1Ra, brain macrophage/microglia bore a quiescent ramified morphology compared to an activated amoeboid morphology in the absence of IL-1Ra (Fig. 7d, e). Thus, following LPS+HI aggression, IL-1Ra shifted from M1 towards M2 phenotype, i.e., towards non-inflammatory and possibly neuroprotective macrophagic/microglial polarization . The induction of an IL-1β-driven macrophage chemokine synthesis, namely MCP-1, was also assessed. A significant rise of MCP-1 was observed following LPS+HI exposure (Fig. 7h, i). IL-1Ra decreased the proportion of cells expressing MCP-1 in neocortical, WM, and striatal areas at 4 h post-HI (Fig. 7h) but the global quantification of MCP-1 expressed within the lesioned cerebral hemisphere did not differ between LPS+HI vs LPS+HI+L-1Ra conditions (Fig. 7i). This is likely due to unbalanced intra- vs extra-cellular distribution of MCP-1 depending on IL-1Ra concentration with an overall lack of impact of IL-1Ra on macrophagic/microglial density (Fig. 7a) in cortical and subcortical affected areas (Fig. 7a).
Role of neuronal MMP-9 in LPS+HI-induced neurotoxicity
Among IL-1β-induced effectors of BBB disruption and neural cell death, MMP-9 has been shown to be particularly important . Forebrains submitted to LPS+HI showed a rise in MMP-9 production compared to Ctl at 48 h post-HI (Fig. 8a, b). Sixty percent of cortical neurons were MMP-9 positive compared to a mere 1 % under Ctl conditions (Fig. 8c). All MMP-9 positive cells were NeuN positive (Fig. 8d) in cortical and deep gray neurons, whereas no double labeling was observed between MMP-9 and astroglial (GFAP) or macrophage/microglial (Iba1) cell markers (data not shown). MMP-9 expression within the LPS+HI exposed brain was fully prevented by IL-1Ra treatment at 48 h (Fig. 8a, b). MMP-9 inhibitor administration exerted a protective effect on both components of ischemic brain injury, namely penumbra and core (Fig. 8e, f). The level of the protective effect of the MMP-9 inhibitor was identical to that of hrIL-1Ra in both core and penumbra lesions of the forebrain (Fig. 8e), meaning that IL-1β and MMP-9 are likely interconnected molecules from the same neuroinflammatory cascade.
Impact of IL-1Ra on cell death mechanisms
LPS+HI acted differently on cell death pathway activations depending on forebrain areas. In the LPS+HI-exposed compared to Ctl neocortex, RIP-3-associated necroptosis occurred at 4 h post-HI (Fig. 9a), whereas no change in activated caspase-3 was detected at 4, 24 (data not shown), or 48 h post-HI (Fig. 9a, b). Within the LPS+HI-exposed compared to Ctl striatum, both RIP-3 (at 4 h post-HI) and activated caspase-3 (at 48 h post-HI) were involved in LPS+HI-induced neural cell death (Fig. 9a, b). In the LPS+HI-exposed vs Ctl WM, RIP-3-associated necroptosis was activated at 4 h post-HI (Fig. 9a, b) whereas activated caspase-3 expression was not affected at 4, 24, and 48 h post-HI. IL-1Ra curbed the expression of activated caspase-3 in the LPS+HI-exposed striatum as well as that of RIP-3-associated necroptosis in the LPS+HI-exposed neocortex and WM (Fig. 9a, b).
Follow-up to P120 revealed no mortality following the hypoxic phase in rats exposed to sole LPS+HI vs LPS+HI+IL-1Ra. Beyond those above mentioned, we observed no particular clinical manifestation between animals exposed to LPS+HI vs LPS+HI+IL-1Ra. Since the first injection of IL-1Ra until 10 days later, there was no significant difference in central body temperature between animals from the Ctl vs LPS+HI vs LPS+HI+IL-1Ra experimental groups (Fig. 10a). This means that the neuroprotective and anti-inflammatory effects we observed during—and following—IL-1Ra administration was not due to hypothermia. IL-1Ra did not affect the weight of LPS+HI animals compared to Ctl at P15, P20, P25, and P100 (Fig. 10b).
Our key findings are that IL-1β and MMP-9 from neuronal origin play a central role in LPS+HI-induced injury of the newborn brain. Neuronal IL-1β might be up-regulated both via mRNA synthesis and NLRP1 inflammasome activation. IL-1Ra (peripherally administered) reaches the brain and interacts directly with neuronal cells to interfere with IL-1β mRNA and protein and MMP-9 synthesis. Neuronal IL-1β up-regulates chemokines (CINC-1, MCP-1), as well as other pro-inflammatory and neurotoxic mediators, namely iNOS and MMP-9. MMP-9—likely in combination with iNOS—might participate to disrupt the BBB [23, 24]. BBB leaks, combined to CINC-1 up-regulation, would facilitate PMN infiltration within the brain. IL-1β modulates macrophages’ polarization since its blockade maintains the M1/M2 balance towards an M2 anti-inflammatory and neuroprotective phenotype. Finally, IL-1β activates neural cell death pathways, namely RIP-3-associated necroptosis and caspase-3-mediated apoptosis. Altogether, these results show that IL-1β and MMP-9 contribute to neuronal self-injury and that their blockade curbs this effect.
Pro-IL-1β is cleaved by a macromolecular complex called the inflammasome for IL-1β secretion to occur . Stimuli triggering inflammasome assembly and activation, within LPS+HI-exposed neurons, could be damage-associated molecular patterns (DAMPs) release due to the release of endogenous molecules following cellular damage such as that induced by LPS+HI . Inflammasome-dependent IL-1β processing relies on distinct NLRs that respond to the intracellular milieu and trigger inflammasome assembly . We showed that NLR expression within neural cells is developmentally regulated, NLRP1 being expressed at P12 (but not P1) within neurons. NLRP3 however was undetected in the P1 or P12 immature brain and only expressed later. Thus, exposure to LPS+HI might release DAMPs within the cytoplasm of neurons leading to exacerbated activation of IL-1β, through NLRP1 inflammasome activation. In addition, LPS might interact with TLR-4 to increase the synthesis of IL-1β via NF-κB activation. Such ability of neurons to produce IL-1β mRNA and protein has also been reported by others in rodents subjected to either HI, traumatic or excitotoxic brain injury [26–28]. Thus, exposure to LPS+HI at a specific term-like stage of brain development may lead to an autocrine/paracrine loop of neuronal self-injury, mediated by IL-1β and subsequent neurotoxic mechanisms such as IL-1β-induced MMP-9 and NO production and/or IL-1β exacerbation of excitotoxic damage [25, 29]. Consistent with such mechanisms, IL-1Ra blockade of the IL-1β signaling pathway decreases the extent of LPS+HI-induced brain injury. Another mechanism whereby IL-1Ra limits LPS+HI-induced injury appears to be by preventing the IL-1β-induced M1 polarization of macrophages .
MMP-9 competitive inhibitor shrunk the size of LPS+HI-induced brain lesions to a same extent as IL-1Ra treatment. MMP-9 induces cell death via anoikis, an integrin-mediated form of caspase-3-induced apoptosis . When the cell loses its tether to the extracellular matrix, anoikis is induced via caspase-9 and the apoptosome . Such a cell death mechanism is relevant to our findings showing LPS+HI-induction of activated caspase-3 and subsequent neuronal cell death—that is preventable by MMP-9 inhibitor treatment. MMP-9 also alters the BBB by degrading the lamina of intra-cerebral blood vessels. Such disruption would enable pro-inflammatory and/or neurotoxic mediators to leak through the BBB and thus increase the extent of intra-cerebral lesions. NO is also known for its deleterious effects on the BBB . Causing a rise of expression of iNOS in LPS+HI brains, together NO and MMP-9 could alter the BBB permeability.
We also observed cerebral expression of TNFα following LPS+HI exposure (data not shown). It is known that TNFα—the synthesis of which is induced by IL-1β—mediates receptor-interacting-protein (RIP) kinase-dependent necroptosis . RIP-1 and -3 associate with TNF receptor-associated death domain (TRADD) and migrate to the mitochondria . This complex releases reactive oxygen species (ROS) and DNAses from the mitochondria, inducing necroptosis . Accordingly, our findings show that RIP-3 expression is increased after LPS+HI. IL-1β-induced MMP-9 (see Fig. 8) also activates necroptosis via FAS-FAS ligand (FASL) interaction through FAS-associated death domain (FADD) [31, 33]. RIP kinases associated with FADD, as well as TRADD, activate necroptosis . Either of these cell death mechanisms might be involved in LPS+HI-induced brain damage in term NE. In human NE, the only current treatment known to be efficient is hypothermia [34, 35]. Hypothermia acts on penumbra but not core lesions in animal models of neonatal HI encephalopathy . In human NE, hypothermia imparts only partial neuroprotection. IL-1Ra, which acts on both, may one day afford additional neuroprotective benefits to hypothermia [34, 35]. However, this needs to be tested in future clinical trials.
Interfering with neuronal IL-1β signaling damped neuroinflammation of core and penumbra brain lesions—switch from M1 to M2 macrophage/microglial polarization and decreased PMN infiltration as well as iNOS and chemokine productions—and alleviated motor impairments. Neuroprotective treatments available against NE are very limited. They mainly consist in symptomatic supportive care and in hypothermia that leave about 50 % of the patients affected by moderate or severe neurobehavioral sequelae. rhIL-1Ra, possibly combined to hypothermia, might be a promising translational option to prevent the severe neurodisabilities complicating NE.
cytokine-induced neutrophil chemoattractant-1
danger-associated molecular pattern
Fas-associated death domain
glial fibrillary acidic protein
ionized calcium-binding adapter molecule 1
interleukin-1 receptor antagonist
inducible nitric oxide synthase
monocyte chemoattractant protein-1
nod-like receptor protein
pathogen-associated molecular pattern
tumor necrosis factor
TNFα receptor-associated death domain
Grether JK, Nelson KB. Maternal infection and cerebral palsy in infants of normal birth weight. JAMA. 1997;278:207–11.
Wintermark P, Boyd T, Gregas MC, Labrecque M, Hansen A. Placental pathology in asphyxiated newborns meeting the criteria for therapeutic hypothermia. Am J Obstet Gynecol. 2010;203:579. e571–579.
Chau V, Poskitt KJ, McFadden DE, Bowen-Roberts T, Synnes A, Brant R, et al. Effect of chorioamnionitis on brain development and injury in premature newborns. Ann Neurol. 2009;66:155–64.
Patel SD, Pierce L, Ciardiello AJ, Vannucci SJ. Neonatal encephalopathy: pre-clinical studies in neuroprotection. Biochem Soc Trans. 2014;42:564–8.
Girard S, Kadhim H, Beaudet N, Sarret P, Sebire G. Developmental motor deficits induced by combined fetal exposure to lipopolysaccharide and early neonatal hypoxia/ischemia: a novel animal model for cerebral palsy in very premature infants. Neuroscience. 2009;158:673–82.
Ferriero DM. Neonatal brain injury. N Engl J Med. 2004;351:1985–95.
Volpe JJ. Brain injury in premature infants: a complex amalgam of destructive and developmental disturbances. Lancet Neurol. 2009;8:110–24.
Aden U, Favrais G, Plaisant F, Winerdal M, Felderhoff-Mueser U, Lampa J, et al. Systemic inflammation sensitizes the neonatal brain to excitotoxicity through a pro-/anti-inflammatory imbalance: key role of TNFalpha pathway and protection by etanercept. Brain Behav Immun. 2010;24:747–58.
Eklind S, Mallard C, Leverin AL, Gilland E, Blomgren K, Mattsby-Baltzer I, et al. Bacterial endotoxin sensitizes the immature brain to hypoxic–ischaemic injury. Eur J Neurosci. 2001;13:1101–6.
Coumans AB, Middelanis JS, Garnier Y, Vaihinger HM, Leib SL, Von Duering MU, et al. Intracisternal application of endotoxin enhances the susceptibility to subsequent hypoxic-ischemic brain damage in neonatal rats. Pediatr Res. 2003;53:770–5.
Wang X, Stridh L, Li W, Dean J, Elmgren A, Gan L, et al. Lipopolysaccharide sensitizes neonatal hypoxic-ischemic brain injury in a MyD88-dependent manner. J Immunol. 2009;183:7471–7.
Larouche A, Roy M, Kadhim H, Tsanaclis AM, Fortin D, Sebire G. Neuronal injuries induced by perinatal hypoxic-ischemic insults are potentiated by prenatal exposure to lipopolysaccharide: animal model for perinatally acquired encephalopathy. Dev Neurosci. 2005;27:134–42.
Towfighi J, Mauger D, Vannucci RC, Vannucci SJ. Influence of age on the cerebral lesions in an immature rat model of cerebral hypoxia-ischemia: a light microscopic study. Brain Res Dev Brain Res. 1997;100:149–60.
Brochu ME, Girard S, Lavoie K, Sebire G. Developmental regulation of the neuroinflammatory responses to LPS and/or hypoxia-ischemia between preterm and term neonates: an experimental study. J Neuroinflammation. 2011;8:55.
Savard A, Lavoie K, Brochu ME, Grbic D, Lepage M, Gris D, et al. Involvement of neuronal IL-1beta in acquired brain lesions in a rat model of neonatal encephalopathy. J Neuroinflammation. 2013;10:110.
Relton JK, Martin D, Thompson RC, Russell DA. Peripheral administration of interleukin-1 receptor antagonist inhibits brain damage after focal cerebral ischemia in the rat. Exp Neurol. 1996;138:206–13.
Lalancette-Hebert M, Gowing G, Simard A, Weng YC, Kriz J. Selective ablation of proliferating microglial cells exacerbates ischemic injury in the brain. J Neurosci. 2007;27:2596–605.
Borlongan CV, Cahill DW, Sanberg PR. Locomotor and passive avoidance deficits following occlusion of the middle cerebral artery. Physiol Behav. 1995;58:909–17.
Chu K, Kim M, Park KI, Jeong SW, Park HK, Jung KH, et al. Human neural stem cells improve sensorimotor deficits in the adult rat brain with experimental focal ischemia. Brain Res. 2004;1016:145–53.
Schroder K, Tschopp J. The inflammasomes. Cell. 2010;140:821–32.
Kigerl KA, Gensel JC, Ankeny DP, Alexander JK, Donnelly DJ, Popovich PG. Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord. J Neurosci. 2009;29:13435–44.
Liu F, McCullough LD. Inflammatory responses in hypoxic ischemic encephalopathy. Acta Pharmacol Sin. 2013;34:1121–30.
Svedin P, Hagberg H, Savman K, Zhu C, Mallard C. Matrix metalloproteinase-9 gene knock-out protects the immature brain after cerebral hypoxia-ischemia. J Neurosci. 2007;27:1511–8.
Jiang Z, Li C, Arrick DM, Yang S, Baluna AE, Sun H. Role of nitric oxide synthases in early blood–brain barrier disruption following transient focal cerebral ischemia. PLoS One. 2014;9, e93134.
Allan SM, Tyrrell PJ, Rothwell NJ. Interleukin-1 and neuronal injury. Nat Rev Immunol. 2005;5:629–40.
Tchelingerian JL, Le Saux F, Jacque C. Identification and topography of neuronal cell populations expressing TNF alpha and IL-1 alpha in response to hippocampal lesion. J Neurosci Res. 1996;43:99–106.
Kadhim H, Tabarki B, De Prez C, Sebire G. Cytokine immunoreactivity in cortical and subcortical neurons in periventricular leukomalacia: are cytokines implicated in neuronal dysfunction in cerebral palsy? Acta Neuropathol. 2003;105:209–16.
Sairanen TR, Lindsberg PJ, Brenner M, Siren AL. Global forebrain ischemia results in differential cellular expression of interleukin-1beta (IL-1beta) and its receptor at mRNA and protein level. J Cereb Blood Flow Metab. 1997;17:1107–20.
Degos V, Peineau S, Nijboer C, Kaindl AM, Sigaut S, Favrais G, et al. G protein-coupled receptor kinase 2 and group I metabotropic glutamate receptors mediate inflammation-induced sensitization to excitotoxic neurodegeneration. Ann Neurol. 2013;73:667–78.
Martinez FO, Sica A, Mantovani A, Locati M. Macrophage activation and polarization. Front Biosci. 2008;13:453–61.
Valentijn AJ, Zouq N, Gilmore AP. Anoikis. Biochem Soc Trans. 2004;32:421–5.
Danjo S, Ishihara Y, Watanabe M, Nakamura Y, Itoh K. Pentylentetrazole-induced loss of blood–brain barrier integrity involves excess nitric oxide generation by neuronal nitric oxide synthase. Brain Res. 2013;1530:44–53.
Kaiser WJ, Upton JW, Mocarski ES. Viral modulation of programmed necrosis. Curr Opin Virol. 2013;3:296–306.
Yager J, Towfighi J, Vannucci RC. Influence of mild hypothermia on hypoxic-ischemic brain damage in the immature rat. Pediatr Res. 1993;34:525–9.
Azzopardi D, Strohm B, Marlow N, Brocklehurst P, Deierl A, Eddama O, et al. Effects of hypothermia for perinatal asphyxia on childhood outcomes. N Engl J Med. 2014;371:140–9.
We thank Karine Belleville and Jean Lainé for their assistance. We thank Jasna Kriz for the in situ hybridization protocol. This work was supported by: Canadian Institutes for Health Research (CIHR), Fonds de la Recherche du Québec—Santé (FRQ-S), Foundation of Stars, Heart and Stroke Foundation Canada, Centre Mère-Enfant de l’Université de Sherbrooke, and Centre des Neurosciences de l’Université de Sherbrooke, Canada. GS is a member of the FRQ-S-funded Centre de Recherche Clinique du CHU de Sherbrooke (CHUS)—.
The authors declare that they have no competing interests.
AS, CG, and MC carried out the experiments. AS performed the statistical analyses. AS and MEB drafted the manuscript. GS conceived the study, coordinated the project, and further edited the manuscript. CG and DG helped to draft the manuscript. All authors read and approved the final manuscript.
About this article
Cite this article
Savard, A., Brochu, M., Chevin, M. et al. Neuronal self-injury mediated by IL-1β and MMP-9 in a cerebral palsy model of severe neonatal encephalopathy induced by immune activation plus hypoxia-ischemia. J Neuroinflammation 12, 111 (2015). https://doi.org/10.1186/s12974-015-0330-8
- Cerebral palsy
- Matrix metalloproteinase-9
- Neonatal encephalopathy